Loading
Cancer Survivorship and Care / Acute Myeloid Leukemia Research / Childhood Cancer Survivors' Quality of Life · Journal article
Nihr Open Research · August 14, 2026
Early or partial results. Treat as a signal, not a conclusion.
This paper describes the development and design of a multimodal personalised prehabilitation care plan (PPCP) for patients with acute myeloid leukaemia and high-risk myelodysplastic syndrome, created using theory-informed methods and extensive patient and healthcare professional input. The intervention is not yet tested for efficacy; a phase III trial is ongoing to evaluate its impact on treatment tolerance, recovery, and quality of life.
Complex intervention development study using Medical Research Council framework. Multidisciplinary team, patients with AML/MDS-EB2, carers, and healthcare professionals in the UK; specific eligibility criteria for patient and HCP participants not detailed in abstract. Intervention: Multimodal personalised prehabilitation care plan (PPCP) including emotional wellbeing, nutrition, exercise, and behavioural support components, tailored by individual assessment, delivered remotely during consolidation chemotherapy and/or…. UK National Health Service setting; specific centres not stated in abstract.
A multimodal personalised prehabilitation care plan was developed including emotional wellbeing, nutrition, exercise, and behavioural support components, tailored by individual assessment Intervention designed for remote delivery as part of consolidation chemotherapy and/or haematopoietic stem cell transplant Phase III trial with internal pilot and embedded process and economic evaluations is ongoing (opened September 2023; trial end date August 2027)
No efficacy, safety, or effectiveness data reported; paper describes development process only
Clinicians should regard this as an intervention framework currently in development; clinical utility and efficacy remain to be demonstrated by the ongoing phase III trial. The design reflects current best practice in complex intervention development but does not yet provide evidence to guide patient care.
This is a development and feasibility study describing the creation of a prehabilitation intervention, not yet reporting efficacy or safety outcomes; the phase III trial is ongoing and will provide the evidence needed to judge clinical impact.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should regard this as an intervention framework currently in development; clinical utility and efficacy remain to be demonstrated by the ongoing phase III trial. The design reflects current best practice in complex intervention development but does not yet provide evidence to guide patient care.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background Acute Myeloid Leukaemia affects approximately 3,100 people annually in the UK. Individuals with high-risk myelodysplastic syndrome (MDS-EB2) receive similar treatment. Curative-intent therapy involves multiple courses of chemotherapy and may include haematopoietic stem cell transplant (HSCT). Treatment tolerance is challenging, with fatigue, muscle loss, poor appetite, and impaired psychological wellbeing common. Prehabilitation may support physical and psychological health, improving treatment tolerance, recovery, fatigue, quality of life, and survival. However, no standardised prehabilitation programme exists for AML/MDS-EB2 within the UK National Health Service. This paper describes the development of a comprehensive, multimodal prehabilitation intervention for individuals with AML and MDS-EB2. Methods The intervention was developed using a theory- and evidence-based approach, underpinned by behavioural science and Acceptance and Commitment Therapy principles. Given limited AML/MDS-EB2-specific prehabilitation literature, development was informed by the wider cancer prehabilitation evidence base. A multidisciplinary team, including patients and carers, followed the Medical Research Council framework for complex intervention development. Guiding principles prioritised patient preferences and minimised delivery burden. A needs assessment included research priority setting, stakeholder engagement, scoping reviews, and surveys of patients and healthcare professionals. Components addressing emotional wellbeing, nutrition, exercise, and behavioural support were developed through literature review, adaptation of existing interventions and guidelines, and extensive patient and carer input. Training materials were developed and intervention delivery rehearsed. Results The intervention includes a multimodal personalised prehabilitation care plan (PPCP) including emotional wellbeing, nutrition, and exercise, as required following assessment, with embedded behavioural support. It is designed to be delivered remotely, as part of consolidation chemotherapy and or HSCT. Conclusions We developed a multi-component, multi-phasic, PPCP for individuals receiving remission consolidation treatment for AML/MDS-EB2 in the PROPEL trial. Patient input was extensive. The PROPEL intervention is being tested in a two-arm multi-centre UK-based phase III trial with internal pilot and embedded process and economic evaluations. Trial registration: ISRCTN Registry 17655532; Registration date: 26/05/2023. PROPEL trial opened September 2023; trial end date August 2027.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.